Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field

Eosinophils and their products play an essential role in the pathogenesis of various reactive and neoplastic disorders. Depending on the underlying disease, molecular defect and involved cytokines, hypereosinophilia may develop and may lead to organ damage. In other patients, persistent eosinophilia is accompanied by typical clinical findings, but the causative role and impact of eosinophilia remain uncertain. For patients with eosinophil-mediated organ pathology, early therapeutic intervention with agents reducing eosinophil counts can be effective in limiting or preventing irreversible organ damage. Therefore, it is important to approach eosinophil disorders and related syndromes early by using established criteria, to perform all appropriate staging investigations, and to search for molecular targets of therapy. In this article, we review current concepts in the pathogenesis and evolution of eosinophilia and eosinophil-related organ damage in neoplastic and non-neoplastic conditions. In addition, we discuss classifications of eosinophil disorders and related syndromes as well as diagnostic algorithms and standard treatment for various eosinophil-related disorders.

[1]  A. Straumann,et al.  Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense , 2008, Nature Medicine.

[2]  G. Gleich Mechanisms of eosinophil-associated inflammation. , 2000, The Journal of allergy and clinical immunology.

[3]  P. Weller,et al.  Functional extracellular eosinophil granules: novel implications in eosinophil immunobiology. , 2009, Current opinion in immunology.

[4]  C. Bachert,et al.  Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. , 1997, Journal of immunology.

[5]  P. Weller,et al.  Practical approach to the patient with hypereosinophilia. , 2010, The Journal of allergy and clinical immunology.

[6]  J. Denburg,et al.  Heterogeneity of human peripheral blood eosinophil-type colonies: evidence for a common basophil-eosinophil progenitor. , 1985, Blood.

[7]  D. Gilliland,et al.  Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. , 2006, Best practice & research. Clinical haematology.

[8]  A. Kay,et al.  Fc gamma and CD11/CD18 receptor expression on normal density and low density human eosinophils. , 1990, Immunology.

[9]  S. Durham,et al.  Identification of messenger RNA for IL-4 in human eosinophils with granule localization and release of the translated product. , 1995, Journal of immunology.

[10]  A. Tefferi Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1 , 2008, Journal of cellular and molecular medicine.

[11]  M. van de Rijn,et al.  Eotaxin Triggers Eosmophil-Selective Chemotaxis and Calcium Flux via a Distinct Receptor and Induces Pulmonary Eosinophilia in the Presence of Interleukin 5 in Mice , 1996, Molecular medicine.

[12]  W. Hofmann,et al.  Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation , 2012, Leukemia.

[13]  S. Schnittger,et al.  Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome – a phase‐II study , 2008, British journal of haematology.

[14]  L. Boon,et al.  Eosinophil differentiation in the bone marrow is inhibited by T cell-derived IFN-gamma. , 2010, Blood.

[15]  F. Luscinskas,et al.  Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules , 1991, The Journal of experimental medicine.

[16]  A. Tefferi,et al.  Eosinophilia: secondary, clonal and idiopathic , 2006, British journal of haematology.

[17]  Gross Wl Churg-Strauss syndrome: update on recent developments. , 2002, Current opinion in rheumatology.

[18]  M. Vadas,et al.  GM-CSF, IL-3 and IL-5: cross-competition on human haemopoietic cells. , 1992, Immunology today.

[19]  B. Bochner,et al.  Human eosinophils express two Siglec-8 splice variants. , 2002, The Journal of allergy and clinical immunology.

[20]  D. Fabbro,et al.  PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. , 2003, Cancer cell.

[21]  J. Boyce,et al.  Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. , 2004, The Journal of allergy and clinical immunology.

[22]  R. Silver Eosinophilia‐myalgia syndrome, toxic‐oil syndrome, and diffuse fasciitis with eosinophilia , 1992, Current opinion in rheumatology.

[23]  L. Scapozza,et al.  A novel FIP1L1‐PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome , 2009, Allergy.

[24]  M. Capron Eosinophils and parasites. , 1991, Annales de parasitologie humaine et comparee.

[25]  A. Wardlaw,et al.  Expression of mRNA and immunoreactivity for the granulocyte/macrophage colony-stimulating factor in activated human eosinophils , 1991, The Journal of experimental medicine.

[26]  Francesca Levi-Schaffer,et al.  Inhibitory receptors on eosinophils: a direct hit to a possible Achilles heel? , 2007, The Journal of allergy and clinical immunology.

[27]  G. Gleich,et al.  Human eosinophil granule major basic protein and its novel homolog , 1998, Allergy. European Journal of Allergy and Clinical Immunology.

[28]  D. Gilliland,et al.  Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias , 2004, Leukemia.

[29]  R. Schleimer,et al.  The effects of the potent glucocorticoid budesonide on adhesion of eosinophils to human vascular endothelial cells and on endothelial expression of adhesion molecules. , 1993, The Journal of pharmacology and experimental therapeutics.

[30]  P. Valent,et al.  Type beta transforming growth factors promote interleukin-3 (IL-3)- dependent differentiation of human basophils but inhibit IL-3-dependent differentiation of human eosinophils , 1992 .

[31]  M. Rothenberg,et al.  Origin, regulation and physiological function of intestinal oeosinophils. , 2008, Best practice & research. Clinical gastroenterology.

[32]  R. Schleimer,et al.  The role of adhesion molecules in human eosinophil and basophil recruitment. , 1994, The Journal of allergy and clinical immunology.

[33]  H. Malech,et al.  Early commitment to the eosinophil lineage by cultured human peripheral blood CD34+ cells: messenger RNA analysis. , 1996, The Journal of allergy and clinical immunology.

[34]  A. B. Kay,et al.  The Eosinophil in Infectious Diseases , 1974 .

[35]  D. Rosing,et al.  Cardiovascular manifestations of hypereosinophilic syndromes. , 2007, Immunology and allergy clinics of North America.

[36]  M. Raffeld,et al.  Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. , 2010, The Journal of allergy and clinical immunology.

[37]  B. Bochner,et al.  Adhesion molecule antagonists: future therapies for allergic diseases? , 1993, The European respiratory journal.

[38]  R. Schleimer,et al.  Studies on the adhesive interaction between purified human eosinophils and cultured vascular endothelial cells. , 1988, Journal of immunology.

[39]  P. Valent,et al.  Developmental, Malignancy-Related, and Cross-Species Analysis of Eosinophil, Mast Cell, and Basophil Siglec-8 Expression , 2011, Journal of Clinical Immunology.

[40]  M. Andersson,et al.  Circulating eosinophil/basophil progenitors and nasal mucosal cytokines in seasonal allergic rhinitis , 1999, Allergy.

[41]  J. Hill,et al.  Glucocorticoid receptors in normal human eosinophils: comparison with neutrophils. , 1981, The Journal of allergy and clinical immunology.

[42]  R. Dummer,et al.  Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. , 1999, The New England journal of medicine.

[43]  S. Wolff,et al.  THE HYPEREOSINOPHILIC SYNDROME: Analysis of Fourteen Cases With Review of The Literature , 1975, Medicine.

[44]  S. Stafford,et al.  Transforming growth factor beta abrogates the effects of hematopoietins on eosinophils and induces their apoptosis , 1994, The Journal of experimental medicine.

[45]  A. Grützkau,et al.  Activation of the specific neurotrophin receptors TrkA, TrkB and TrkC influences the function of eosinophils , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[46]  T. Nutman,et al.  Evaluation and differential diagnosis of marked, persistent eosinophilia. , 2012, Seminars in hematology.

[47]  D. Staunton,et al.  αdβ2 Integrin Is Expressed on Human Eosinophils and Functions as an Alternative Ligand for Vascular Cell Adhesion Molecule 1 (VCAM-1) , 1998, The Journal of experimental medicine.

[48]  J. Denburg Microenvironmental influences on inflammatory cell differentiation , 1995, Allergy.

[49]  P. Valent Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. , 2009, Blood reviews.

[50]  M. Goldman,et al.  Hypereosinophilic syndromes , 2007, Orphanet journal of rare diseases.

[51]  W. Gross Churg-Strauss syndrome: update on recent developments. , 2002, Current opinion in rheumatology.

[52]  A. Kosar,et al.  Eosinophilia in rheumatologic diseases: a prospective study of 1000 cases , 2004, Rheumatology International.

[53]  M. Isobe,et al.  Intercellular adhesion molecule‐1 on eosinophils is involved in eosinophil protein X release induced by cytokines , 1997, Immunology.

[54]  B. Bain Review: eosinophils and eosinophilic leukemia. , 2010, Clinical advances in hematology & oncology : H&O.

[55]  P. Valent The phenotype of human eosinophils, basophils, and mast cells. , 1994, The Journal of allergy and clinical immunology.

[56]  M. Lotze,et al.  Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. , 2007, Journal of immunotherapy.

[57]  H. Simon,et al.  Eosinophil extracellular DNA traps in skin diseases. , 2011, The Journal of allergy and clinical immunology.

[58]  T. Haferlach,et al.  The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers , 2007, Annals of Hematology.

[59]  Kazuhiko Yamamoto,et al.  Changing expression of IL-3 and IL-5 receptors in cultured human eosinophils. , 2003, Biochemical and biophysical research communications.

[60]  P. Marynen,et al.  FIP1L1-PDGFRα D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRα T674I eosinophilic leukemia with single agent sorafenib , 2009, Leukemia.

[61]  Choon-Sik Park,et al.  Interferon-γ Inhibits in vitro Mobilization of Eosinophils by Interleukin-5 , 2005, International Archives of Allergy and Immunology.

[62]  D. Creamer,et al.  Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking , 2011, Clinical and experimental dermatology.

[63]  S. Durham,et al.  Eosinophils and eosinophil-associated cytokines in allergic inflammation. , 1997, International archives of allergy and immunology.

[64]  Kenji Matsumoto,et al.  Regulation of α4 integrin–mediated adhesion of human eosinophils to fibronectin and vascular cell adhesion molecule-1 , 1997 .

[65]  L. Krupp,et al.  Eosinophilia‐myalgia syndrome, toxic‐oil syndrome, and diffuse fasciitis with eosinophilia , 1995, Current opinion in rheumatology.

[66]  K. Willard-Gallo,et al.  Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome , 2000, British journal of haematology.

[67]  R. L. Barker,et al.  The molecular biology of eosinophil granule proteins. , 1991, International archives of allergy and applied immunology.

[68]  Peter Marynen,et al.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.

[69]  A. Tefferi,et al.  Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms , 2008, Leukemia.

[70]  K. Ohta,et al.  Expression and Function of Toll-Like Receptors in Eosinophils: Activation by Toll-Like Receptor 7 Ligand 1 , 2003, The Journal of Immunology.

[71]  L. Guillevin,et al.  Churg–Strauss syndrome: evidence for disease subtypes? , 2010, Current opinion in rheumatology.

[72]  H. Kantarjian,et al.  A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia , 2007, Cancer.

[73]  M. Feldmann,et al.  T cells and lymphokines. , 1989, British medical bulletin.

[74]  A. Tefferi Modern Diagnosis and Treatment of Primary Eosinophilia , 2005, Acta Haematologica.

[75]  A. Reiter,et al.  Fibroblast Growth Factor Receptor and Platelet-Derived Growth Factor Receptor Abnormalities in Eosinophilic Myeloproliferative Disorders , 2008, Acta Haematologica.

[76]  S. Georas,et al.  Eosinophil transendothelial migration induced by cytokines. I. Role of endothelial and eosinophil adhesion molecules in IL-1 beta-induced transendothelial migration. , 1992, Journal of immunology.

[77]  T. Schall,et al.  RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes , 1992, The Journal of experimental medicine.

[78]  C. Feistritzer,et al.  Expression and function of the vascular endothelial growth factor receptor FLT-1 in human eosinophils. , 2004, American journal of respiratory cell and molecular biology.

[79]  A. Chase,et al.  Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. , 2007, Blood.

[80]  N. Bovin,et al.  Eosinophil-Selective Binding and Proapoptotic Effect in Vitro of a Synthetic Siglec-8 Ligand, Polymeric 6′-Sulfated Sialyl Lewis X , 2009, Journal of Pharmacology and Experimental Therapeutics.

[81]  T. Colby,et al.  Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis. , 1992, The American journal of pathology.

[82]  T. Fujisawa,et al.  Inhibitory effect of transforming growth factor beta 1 on cytokine-enhanced eosinophil survival and degranulation. , 1995, International archives of allergy and immunology.

[83]  B. Bain,et al.  Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. , 2002, The New England journal of medicine.

[84]  W Newman,et al.  Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. , 1996, The Journal of clinical investigation.

[85]  Y. Numagami,et al.  Sinus thrombosis in idiopathic hypereosinophilic syndrome causing fatal cerebral haemorrhage , 2008, Journal of Clinical Neuroscience.

[86]  D. Chi,et al.  The role of human mast cell-derived cytokines in eosinophil biology. , 2004, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[87]  B. Bochner,et al.  The surface phenotype of human eosinophils. , 2000, Chemical immunology.

[88]  R. Schleimer,et al.  Mast cells, basophils, and eosinophils: distinct but overlapping pathways for recruitment , 2001, Immunological reviews.

[89]  T. Ganz,et al.  Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. , 1989, Journal of immunology.

[90]  J. Byström,et al.  Plasminogen activator inhibitor‐2 (PAI‐2) in eosinophilic leukocytes , 2004, Journal of leukocyte biology.

[91]  G. Gleich,et al.  DEPOSITS OF EOSINOPHIL GRANULE PROTEINS IN CARDIAC TISSUES OF PATIENTS WITH EOSINOPHILIC ENDOMYOCARDIAL DISEASE , 1987, The Lancet.

[92]  M. Goldman,et al.  The hypereosinophilic syndrome revisited. , 2003, Annual review of medicine.

[93]  R. Schleimer,et al.  Comparison of human eosinophil and neutrophil ligands for P-selectin: ligands for P-selectin differ from those for E-selectin. , 1995, American journal of respiratory cell and molecular biology.

[94]  E. Tabouret,et al.  Low-dose Nilotinib can maintain complete molecular remissions in FIP1L1/PDGFRA-positive hypereosinophilic syndrome. , 2011, Leukemia research.

[95]  A. Vaglio,et al.  Eosinophilic myocarditis in a patient with idiopathic hypereosinophilic syndrome: insights into mechanisms of myocardial cell death. , 2004, Human pathology.

[96]  D. Gilliland,et al.  CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. , 2003, Blood.

[97]  O. Götze,et al.  The biologic role of interleukin-8: functional analysis and expression of CXCR1 and CXCR2 on human eosinophils. , 1999, Blood.

[98]  B. Bochner Siglec‐8 on human eosinophils and mast cells, and Siglec‐F on murine eosinophils, are functionally related inhibitory receptors , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[99]  P. Murdock,et al.  Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils. , 2000, The Journal of allergy and clinical immunology.

[100]  J. Denburg Hemopoietic progenitors and cytokines in allergic inflammation , 1998, Allergy.

[101]  H. J. Wilkins,et al.  Hypereosinophilic syndrome: An update , 2005, American journal of hematology.

[102]  G. Walsh,et al.  Advances in the immunobiology of eosinophils and their role in disease. , 1999, Critical reviews in clinical laboratory sciences.

[103]  V. Cottin,et al.  Churg-Strauss Syndrome , 2004, Seminars in respiratory and critical care medicine.

[104]  C. Bizer,et al.  Eosinophils Express Functional IL-13 in Eosinophilic Inflammatory Diseases1 , 2002, The Journal of Immunology.

[105]  M. Vadas,et al.  Interleukin-5, interleukin-3, and granulocyte-macrophage colony-stimulating factor cross-compete for binding to cell surface receptors on human eosinophils. , 1991, The Journal of biological chemistry.

[106]  T. Graf,et al.  Making Eosinophils Through Subtle Shifts in Transcription Factor Expression , 2002, The Journal of experimental medicine.

[107]  M. Peters,et al.  Ultrastructural study of eosinophils from patients with the hypereosinophilic syndrome: a morphological basis of hypodense eosinophils. , 1988, Blood.

[108]  P. Proost,et al.  Human monocyte chemotactic proteins-2 and 3 (MCP-2 and MCP-3) attract human eosinophils and desensitize the chemotactic responses towards RANTES. , 1994, Biochemical and biophysical research communications.

[109]  S. Phipps,et al.  Eosinophils: Biological Properties and Role in Health and Disease , 2008, Clinical and Experimental Allergy.

[110]  B. Bain,et al.  Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. , 2007, Immunology and allergy clinics of North America.

[111]  D. MacGlashan,et al.  Macrophage-derived chemokine induces human eosinophil chemotaxis in a CC chemokine receptor 3- and CC chemokine receptor 4-independent manner. , 1999, The Journal of allergy and clinical immunology.

[112]  A. B. Kay,et al.  The eosinophil in infection diseases. , 1974, The Journal of infectious diseases.

[113]  M. Ogawa,et al.  Identification of pure and mixed basophil colonies in culture of human peripheral blood and marrow cells. , 1984, Blood.

[114]  M. Rondoni,et al.  Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. , 2007, Blood.

[115]  J. Sheikh,et al.  Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. , 2009, The Journal of allergy and clinical immunology.

[116]  E. Baxter,et al.  Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. , 2003, Blood.

[117]  G. Gleich,et al.  What targeting eosinophils has taught us about their role in diseases. , 2010, The Journal of allergy and clinical immunology.

[118]  A. Capron,et al.  Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease , 1992, The Journal of experimental medicine.

[119]  A. Klion Hypereosinophilic syndrome: current approach to diagnosis and treatment. , 2009, Annual review of medicine.

[120]  S. Woo,et al.  Human Eosinophils Show Chemotaxis to Lymphoid Chemokines and Exhibit Antigen-Presenting-Cell-Like Properties upon Stimulation with IFN-γ, IL-3 and GM-CSF , 2008, International Archives of Allergy and Immunology.

[121]  H. Kantarjian,et al.  Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia , 2009, Clinical Cancer Research.

[122]  P. Weller,et al.  Eosinophils: structure and functions. , 1994, Current opinion in immunology.

[123]  A. Macisaac,et al.  Obstructive prosthetic mitral valve thrombosis in idiopathic hypereosinophilic syndrome: a case report and review of the literature. , 2006, The Journal of heart valve disease.

[124]  T. Sugiura,et al.  Chemotaxis of Human Peripheral Blood Eosinophils to 2-Arachidonoylglycerol: Comparison with Other Eosinophil Chemoattractants , 2006, International Archives of Allergy and Immunology.

[125]  H. Simon,et al.  Novel approaches to therapy of hypereosinophilic syndromes. , 2007, Immunology and allergy clinics of North America.

[126]  H. Simon,et al.  Eosinophilic disorders. , 2007, The Journal of allergy and clinical immunology.

[127]  Lin Ying Liu,et al.  Human Airway Eosinophils Respond to Chemoattractants with Greater Eosinophil-Derived Neurotoxin Release, Adherence to Fibronectin, and Activation of the Ras–ERK Pathway When Compared with Blood Eosinophils , 2010, The Journal of Immunology.

[128]  H. Simon,et al.  Eosinophil and neutrophil extracellular DNA traps in human allergic asthmatic airways. , 2011, The Journal of allergy and clinical immunology.

[129]  Jiong Hu,et al.  FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib. , 2008, Chinese medical journal.

[130]  A. Reiter,et al.  Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders , 2007, Haematologica.

[131]  C. Ferland,et al.  IL-16 Activates Plasminogen-Plasmin System and Promotes Human Eosinophil Migration into Extracellular Matrix via CCR3-Chemokine-Mediated Signaling and by Modulating CD4 Eosinophil Expression1 , 2004, The Journal of Immunology.

[132]  P. Marynen,et al.  Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant , 2006 .

[133]  T. Haferlach,et al.  Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. , 2012, The Journal of allergy and clinical immunology.

[134]  D. Fabbro,et al.  PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[135]  S. Ackerman,et al.  Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. , 2007, Immunology and allergy clinics of North America.

[136]  H. Simon,et al.  Refining the definition of hypereosinophilic syndrome. , 2010, The Journal of allergy and clinical immunology.

[137]  R. Callard,et al.  Recombinant human interleukin 5 is an eosinophil differentiation factor but has no activity in standard human B cell growth factor assays , 1987, European journal of immunology.

[138]  J. Parkin,et al.  Treatment of patients with the hypereosinophilic syndrome with mepolizumab. , 2008, The New England journal of medicine.

[139]  H. Sarau,et al.  Identification of Potent, Selective Non-peptide CC Chemokine Receptor-3 Antagonist That Inhibits Eotaxin-, Eotaxin-2-, and Monocyte Chemotactic Protein-4-induced Eosinophil Migration* , 2000, The Journal of Biological Chemistry.

[140]  N. Talley,et al.  Eosinophil infiltration and degranulation in normal human tissue , 1998, The Anatomical record.

[141]  S. Okubo,et al.  Clinical spectrum and endomyocardial biopsy findings in eosinophilic heart disease , 2005, Heart and Vessels.

[142]  Christian J Wiedermann,et al.  Expression and function of the angiopoietin receptor Tie-2 in human eosinophils. , 2004, The Journal of allergy and clinical immunology.

[143]  C. Peschel,et al.  The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). , 2006, Blood.

[144]  C. Preudhomme,et al.  The severity of FIP1L1–PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus , 2007, Leukemia.

[145]  Y. Levo,et al.  Eosinophilia: A study of 100 hospitalized patients. , 2007, European journal of internal medicine.

[146]  R. Schleimer,et al.  The effects of glucocorticoids on human eosinophils. , 1994, The Journal of allergy and clinical immunology.

[147]  P. Weller,et al.  Human eosinophils constitutively express multiple Th1, Th2, and immunoregulatory cytokines that are secreted rapidly and differentially , 2008, Journal of leukocyte biology.

[148]  A. Minty,et al.  Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating chemokine , 1994, The Journal of experimental medicine.

[149]  Ji Ming Wang,et al.  Recombinant human interleukin 5 is a selective eosinophil chemoattractant , 1989, European journal of immunology.

[150]  Philipp Erben,et al.  Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. , 2011, Blood.

[151]  J. Cools,et al.  Five years since the discovery of FIP1L1–PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias , 2008, Leukemia.

[152]  G. Superti-Furga,et al.  Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. , 2008, Experimental hematology.

[153]  牧野 荘平,et al.  Eosinophils : biological and clinical aspects , 1993 .

[154]  A. Donnenberg,et al.  Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[155]  A. Kay,et al.  Eotaxin (CCL11) and Eotaxin-2 (CCL24) Induce Recruitment of Eosinophils, Basophils, Neutrophils, and Macrophages As Well As Features of Early- and Late-Phase Allergic Reactions Following Cutaneous Injection in Human Atopic and Nonatopic Volunteers1 , 2002, The Journal of Immunology.

[156]  Xiangshan Fan,et al.  [Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1]. , 2012, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[157]  M. K. Bach,et al.  Activation of human eosinophils by platelet-derived growth factor. , 1992, International archives of allergy and immunology.

[158]  A. Capron,et al.  Heterogeneity of human eosinophil glucocorticoid receptor expression in hypereosinophilic patients: absence of detectable receptor correlates with resistance to corticotherapy. , 1989, Clinical and experimental immunology.

[159]  J. Silver,et al.  Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. , 1992, Blood.

[160]  J. Ring,et al.  Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. , 2003, The New England journal of medicine.

[161]  H. Kita,et al.  Transmigration of eosinophils through basement membrane components in vitro: synergistic effects of platelet-activating factor and eosinophil-active cytokines. , 1997, American journal of respiratory cell and molecular biology.

[162]  D. Watkin,et al.  REHABILITATION IN SCHIZOPHRENIA. , 1965, Lancet.

[163]  H. Liapis,et al.  Thrombotic microangiopathy associated with the hypereosinophilic syndrome. , 2005, Kidney international.

[164]  R. Dixon,et al.  Inhibition of adhesion of human neutrophils and eosinophils to P-selectin by the sialyl Lewis antagonist TBC1269: preferential activity against neutrophil adhesion in vitro. , 2000, The Journal of allergy and clinical immunology.

[165]  E. Belongia,et al.  The eosinophilia-myalgia syndrome revisited. , 1996, The Journal of rheumatology.

[166]  M. Seminario,et al.  Expression and function of beta 1 integrins on human eosinophils. , 1997, Memorias do Instituto Oswaldo Cruz.

[167]  U. Jäger,et al.  Improvement of cardiac function, mitral regurgitation and pulmonary hypertension in a patient with chronic eosinophilic leukemia (CEL) after low dose imatinib therapy. , 2008, Leukemia research.

[168]  B. Bain Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1 , 2010, Haematologica.

[169]  P. Valent,et al.  Interleukin-3 is a differentiation factor for human basophils. , 1989, Blood.

[170]  G. Del Prete Human Th1 and Th2 lymphocytes: their role in the pathophysiology of atopy. , 1992, Allergy.

[171]  Sandra A. Moore,et al.  The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRβ and FIP1L1-PDGFRα in vitro and in vivo , 2005 .

[172]  G. Gleich,et al.  The biology of the eosinophilic leukocyte. , 1993, Annual review of medicine.

[173]  K. Sotlar,et al.  Eosinophil, basophil, and mast cell infiltrates in the bone marrow: crossing the boundaries of diagnosis , 2011 .

[174]  E. Knol,et al.  Comparison of human eosinophil and neutrophil adhesion to endothelial cells under nonstatic conditions. Role of L-selectin. , 1994, Journal of immunology.

[175]  B. Bochner,et al.  Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. , 2003, Blood.

[176]  J. Cools,et al.  The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11) , 2010, Haematologica.

[177]  F. Levi-Schaffer,et al.  Cytokine generation by eosinophils. , 1994, The Journal of allergy and clinical immunology.

[178]  H. Simon,et al.  Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. , 2006, The Journal of allergy and clinical immunology.

[179]  B. Bochner Systemic activation of basophils and eosinophils: markers and consequences. , 2000, The Journal of allergy and clinical immunology.

[180]  A. J. Robinson,et al.  Fluvastatin and lovastatin inhibit granulocyte macrophage–colony stimulating factor‐stimulated human eosinophil adhesion to inter‐cellular adhesion molecule‐1 under flow conditions , 2009, Clinical and Experimental Allergy.

[181]  H. Kita Eosinophils: multifaceted biological properties and roles in health and disease , 2011, Immunological reviews.